URGNÂ – UroGen Pharma Ltd.
UroGen Pharma Ltd.URGN
$9.99Name : UroGen Pharma Ltd.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $460,613,920.00
EPSttm : -2.96
UroGen Pharma Ltd.
$9.99
1.48%$0.15Float Short %
13.12
Margin Of Safety %
Put/Call OI Ratio
0.28
EPS Next Q Diff
0.01
EPS Last/This Y
0.09
EPS This/Next Y
2.35
Price
10.14
Target Price
32.62
Analyst Recom
1.25
Performance Q
-0.98
Relative Volume
1.76
Beta
0.64
Ticker: URGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | URGN | 10.59 | 0.09 | 2.04 | 5773 |
| 2025-04-15 | URGN | 10.75 | 0.10 | 8.00 | 5866 |
| 2025-04-16 | URGN | 10.4 | 0.10 | 7.64 | 5871 |
| 2025-04-17 | URGN | 9.66 | 0.11 | 0.39 | 5916 |
| 2025-04-18 | URGN | 9.67 | 0.11 | 0.39 | 5916 |
| 2025-04-21 | URGN | 9.62 | 0.09 | 0.33 | 5668 |
| 2025-04-22 | URGN | 10.03 | 0.09 | 0.59 | 5716 |
| 2025-04-23 | URGN | 10.19 | 0.10 | 0.00 | 5771 |
| 2025-04-24 | URGN | 10.1 | 0.10 | 0.07 | 5783 |
| 2025-04-25 | URGN | 9.87 | 0.096883214419827 | 0.68421052631579 | 5842 |
| 2025-04-28 | URGN | 11.26 | 0.09904512263621 | 1.4356846473029 | 5870 |
| 2025-04-29 | URGN | 10.74 | 0.16 | 0.12 | 6350 |
| 2025-04-30 | URGN | 11.66 | 0.16 | 0.18 | 6356 |
| 2025-05-01 | URGN | 11.42 | 0.18 | 0.56 | 6640 |
| 2025-05-02 | URGN | 11.5 | 0.18 | 1.80 | 6748 |
| 2025-05-05 | URGN | 10.94 | 0.21 | 8.15 | 6915 |
| 2025-05-06 | URGN | 9.68 | 0.23 | 3.42 | 7081 |
| 2025-05-07 | URGN | 10.11 | 0.29 | 0.27 | 7381 |
| 2025-05-08 | URGN | 10.66 | 0.28 | 0.03 | 7720 |
| 2025-05-09 | URGN | 10.36 | 0.28 | 0.48 | 7757 |
| 2025-05-12 | URGN | 11.14 | 0.29 | 0.52 | 8193 |
| 2025-05-13 | URGN | 10.12 | 0.28 | 0.76 | 8769 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | URGN | 10.60 | 18.0 | - | -2.88 |
| 2025-04-15 | URGN | 10.75 | 18.0 | - | -2.88 |
| 2025-04-16 | URGN | 10.40 | 18.0 | - | -2.88 |
| 2025-04-17 | URGN | 9.67 | 18.0 | - | -2.88 |
| 2025-04-18 | URGN | 9.67 | 18.0 | - | -2.88 |
| 2025-04-21 | URGN | 9.63 | 18.0 | - | -2.88 |
| 2025-04-22 | URGN | 10.05 | 18.0 | - | -2.88 |
| 2025-04-23 | URGN | 10.20 | 18.0 | - | -2.88 |
| 2025-04-24 | URGN | 10.10 | 18.0 | - | -2.88 |
| 2025-04-25 | URGN | 9.87 | 18.0 | - | -2.88 |
| 2025-04-28 | URGN | 11.26 | 18.0 | - | -2.88 |
| 2025-04-29 | URGN | 10.76 | 18.0 | - | -2.88 |
| 2025-04-30 | URGN | 11.64 | 18.0 | - | -2.88 |
| 2025-05-01 | URGN | 11.41 | 18.0 | - | -2.88 |
| 2025-05-02 | URGN | 11.51 | 18.0 | - | -2.88 |
| 2025-05-05 | URGN | 10.95 | 18.0 | - | -2.88 |
| 2025-05-06 | URGN | 9.67 | 18.0 | - | -2.88 |
| 2025-05-07 | URGN | 10.12 | 18.0 | - | -2.88 |
| 2025-05-08 | URGN | 10.68 | 18.0 | - | -2.88 |
| 2025-05-09 | URGN | 10.38 | 18.0 | - | -2.88 |
| 2025-05-12 | URGN | 11.14 | 18.0 | - | -2.88 |
| 2025-05-13 | URGN | 10.14 | 18.0 | - | -2.88 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | URGN | -0.15 | 3.41 | 14.79 |
| 2025-04-15 | URGN | -0.15 | 3.41 | 14.79 |
| 2025-04-16 | URGN | -0.15 | 3.41 | 14.79 |
| 2025-04-17 | URGN | -0.15 | 3.41 | 14.79 |
| 2025-04-18 | URGN | -0.15 | 3.41 | 14.79 |
| 2025-04-21 | URGN | -0.15 | 3.83 | 14.79 |
| 2025-04-22 | URGN | -0.15 | 3.83 | 14.79 |
| 2025-04-23 | URGN | -0.15 | 3.83 | 14.79 |
| 2025-04-24 | URGN | -0.15 | 3.83 | 14.79 |
| 2025-04-25 | URGN | -0.15 | 3.83 | 14.79 |
| 2025-04-28 | URGN | -0.15 | 2.56 | 13.24 |
| 2025-04-29 | URGN | -0.15 | 2.56 | 13.24 |
| 2025-04-30 | URGN | -0.15 | 2.56 | 13.24 |
| 2025-05-01 | URGN | -0.15 | 2.56 | 13.24 |
| 2025-05-02 | URGN | -0.15 | 2.56 | 13.24 |
| 2025-05-05 | URGN | -0.15 | 2.16 | 13.23 |
| 2025-05-06 | URGN | -0.15 | 2.16 | 13.23 |
| 2025-05-07 | URGN | -0.15 | 2.16 | 13.23 |
| 2025-05-08 | URGN | -0.15 | 2.16 | 13.23 |
| 2025-05-09 | URGN | -0.15 | 2.16 | 13.23 |
| 2025-05-12 | URGN | -0.15 | 2.38 | 13.12 |
| 2025-05-13 | URGN | -0.15 | 2.38 | 13.12 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
-0.8
Avg. EPS Est. Current Quarter
-0.8
Avg. EPS Est. Next Quarter
-0.79
Insider Transactions
-0.15
Institutional Transactions
2.38
Beta
0.64
Average Sales Estimate Current Quarter
22
Average Sales Estimate Next Quarter
24
Fair Value
Quality Score
28
Growth Score
52
Sentiment Score
89
Actual DrawDown %
67.2
Max Drawdown 5-Year %
-82.8
Target Price
32.62
P/E
Forward P/E
PEG
P/S
5.09
P/B
P/Free Cash Flow
EPS
-3.18
Average EPS Est. Cur. Y​
-2.88
EPS Next Y. (Est.)
-0.52
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-150.68
Relative Volume
1.76
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
UroGen Pharma Ltd.Sector: Healthcare
Industry: Biotechnology
Employees: 234
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
stock quote shares URGNÂ – UroGen Pharma Ltd. Stock Price stock today
news today URGNÂ – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025
marketwatch URGNÂ – UroGen Pharma Ltd. yahoo finance google finance
stock history URGNÂ – UroGen Pharma Ltd. invest stock market
stock prices URGN premarket after hours
ticker URGN fair value insiders trading